COLLEGIO DI DIREZIONE - Azienda Ospedaliera di Parma

20) Favaloro, EJ; Funk, DM; Lippi, G (2012) Pre-analytical Variables in Coagulation Testing Associated
With Diagnostic Errors in Hemostasis LABMEDICINE 43(2):54-60 IF=0.267 [Article]
The use of modern laboratory instrumentation with high levels of test reliability and appropriate quality assurance
measures will lead to very few analytical errors within hemostasis testing. Nevertheless, incorrect or inappropriate test
results are still reported, often due to events outside the control of the laboratories performing the tests. This is due
primarily to pre-analytical events associated with sample collection and processing, as well as post-analytical events
related to the reporting and interpretation of test results. This review focuses on the pre-analytical phase, highlighting
contributory elements and providing suggestions on how problems can be minimized or prevented, thereby improving
the likelihood that reported test results actually represent the true clinical status of the patient rather than that of an
inappropriate sample. This review should be of value to both laboratory personnel and clinicians because an
appreciation of these issues will enable the optimal clinical management of patients.
21) Ferri, A; Ferri, T; Sesenna, E (2012) Bilateral Silent Sinus Syndrome: Case Report and Surgical
Solution JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY 70(1):E103-E106 IF=1.5 [Article]
abstract non disponibile
22) Franchini, M; Tagliaferri, A; Mengoli, C; Cruciani, M (2012) Cumulative inhibitor incidence in
previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant
factor VIII concentrates: A critical systematic review CRITICAL REVIEWS IN ONCOLOGY
HEMATOLOGY 81(1):82-93 IF=4.689 [Review]
Inhibitor development represents currently the most serious and challenging complication of clotting factor replacement
therapy. A number of studies have analyzed the impact of the type of factor VIII (FVIII) replacement therapy (plasmaderived
versus recombinant concentrates) on inhibitor development in hemophilia A patients with conflicting results. In
order to shed light on this controversial issue, we performed a systematic review and meta-analysis on the published
prospective studies evaluating the incidence rate of inhibitors in previously untreated patients (PUPs) with severe
hemophilia A. Data from a total of 800 patients enrolled in 25 prospective studies published between 1990 and 2007
were included in this review. The quality of the studies was evaluated using two different systems: the Newcastle-
Ottawa Scale (NOS) and STrengthening the Reporting of OBservational studies in Epidemiology (STROBE). Overall,
the inhibitor incidence rate did not differ significantly between recipients of plasma-derived and recombinant FVIII
concentrates (weighted means: 21%; 95% CI, 14-30 versus 27%; 95% CI, 21-33). Similarly, high titer inhibitors did not
differ significantly between patients treated with plasma-derived (weighted means: 14%; 95% CI, 8-25) or recombinant
FVIII concentrates (weighted means: 16%; 95% CI, 13-20). Thus, the main conclusion of this systematic review
performed using selective criteria is that the type of FVIII product (i.e., plasma-derived versus recombinant FVIII
concentrates) does not seem to influence the inhibitor rate in PUPs with severe hemophilia A. (C) 2011 Elsevier Ireland
Ltd. All rights reserved.
23) Franzini, L; Ardigo, D; Valtuena, S; Pellegrini, N; Del Rio, D; Bianchi, MA; Scazzina, F; Piatti, PM;
Brighenti, F; Zavaroni, I (2012) Food selection based on high total antioxidant capacity improves